Article
Bioequivalence Evaluation of Generic Febuxostat versus Feburic ® in Healthy Chinese Subjects: A Randomized Crossover Study
2025-05-21
Abstract excerpt
<title>Abstract</title> <p><bold>Purpose</bold> Febuxostat, a xanthine oxidase inhibitor, is a first-line treatment for gout with hyperuricemia. This study evaluated the pharmacokinetic (PK) bioequivalence, safety profile, and food effects of a generic febuxostat formulation compared to the reference product (Feburic®) in healthy Chinese volunteers <bold>Patients and Methods</bold> In this randomized, open-label,...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0c67d2c3-ca3a-51d5-a186-4376b704fbf1
- DOI
- 10.21203/rs.3.rs-6492168/v1
